Cerus Corp. shares rose 17.6% in Wednesday trade after the company said a late-stage clinical trial evaluating the company’s Intercept treatment for chronic anemia in patients with the inherited blood disorder thalassemia had positive results. In the phase 3 trial, which enrolled 86 patients, individuals with Intercept-treated red blood cells met the trial’s primary efficacy and safety endpoints, the company said. The company plans to file for commercialization in Europe in the second half of this year. Cerus shares have surged 77.4% over the last three months, compared with a 10.5% rise in the S&P 500 and a 11.8% rise in the Dow Jones Industrial Average .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News